Can I use my own phage library in your screening service?

Yes, we accept client-supplied libraries pending QC review. We also offer in-house libraries for peptides and antibody fragments.

What animal models do you support for muscle targeting?

We commonly use mice and rats for muscle targeting studies, including both healthy and disease-specific models. Other species can be discussed case-by-case.

How long does the screening process take?

Typical turnaround time is 6–10 weeks, depending on the number of selection rounds and scope of validation.

Can you differentiate between cardiac and skeletal muscle in selection?

Yes. By tailoring the tissue harvesting and circulation protocol, we can isolate tissue-specific binders for either or both muscle types.

Will I retain IP rights to the peptides discovered?

Yes. Creative Biolabs operates under strict confidentiality, and all sequences and results identified during your project remain your intellectual property.

Muscle Targeting In Vivo Phage Library Screening Service

Introduction Our Services Workflow Platform Advantages Deliverables FAQ Resources

Introduction

The muscle tissue is deeply involved in many diseases and therapeutic presentations, from metabolic disorders to muscular dystrophies, up to conceptual areas like regenerative medicine or drug delivery systems. Nevertheless, muscle tissue is not an easy tissue to target specifically with respect to the generation of precision therapeutics. Let Creative Biolabs offer you the extraordinary Muscle Targeting In Vivo Phage Display Screening Custom Service to assist you with muscle-restricted peptide ligands or antibody fragments under physiological conditions.

Creative Biolab has a strong platform for muscle targeting based on our years of experience in the phage display field. With respect to gene therapy vectors, nanoparticle delivery, tissue-specific targeting, or biomarker discovery, our team facilitates research needs with informed technical guidance and scientifically sound strategies.

Our Services

At Creative Biolabs, we focus on precision and performance. We have an in vivo phage display muscle targeting service built upon it — so that the screening of both peptide and monoclonal antibody libraries in the live animal model can be done in real time.

It is an approach that is ideally suited for identifying both the muscles that bind and utilize natural pathways to access those unanticipated sites of presentation.

Key features of our muscle targeting services include:

In vivo screening using high-diversity phage display libraries
Identification of peptides or scFv fragments that preferentially accumulate in skeletal or cardiac muscle
Optional comparison across healthy and diseased muscle tissue (e.g., models of muscular dystrophy, cachexia, etc.)
Sequence analysis and ligand validation
Custom follow-up validation studies (e.g., immunofluorescence, biodistribution)

This service is part of Creative Biolabs' broader in vivo phage display offering, which also includes:

In Vivo Phage Display for Tumor Targeting	In Vivo Phage Display for Atherosclerosis Targeting
In Vivo Phage Display for Human Synovium Targeting	In Vivo Phage Display for Vascular Endothelium Targeting

We're here to help if you'd like more information.

Workflow

Creative Biolabs' muscle-targeting workflow is designed for scientific rigor and flexibility. Our step-by-step process ensures that you receive relevant, validated, and actionable ligands:

Project consultation & experimental design

We tailor the strategy based on the muscle subtype, animal model, disease state, and delivery route.

Phage library preparation

Selection from our validated libraries (random peptide or antibody-based), or use of client-provided libraries.

In vivo administration & circulation

The library is introduced via systemic injection into the chosen animal model. Circulation is allowed for a defined period to enable interaction with tissues.

Tissue harvesting & phage recovery

Target and non-target tissues are collected. Muscle-associated phage clones are isolated, amplified, and subjected to iterative rounds of selection.

DNA sequencing & bioinformatics

High-throughput sequencing of recovered clones is performed to identify enriched sequences.

Candidate analysis & validation (optional)

Validation includes ELISA, tissue staining, or in vivo imaging, depending on project goals.

Fig.5 Phage-based screening of peptides for muscle targeting. (Creative Biolabs Original) Fig.1 Screening for peptides aiming at muscle targeting. (Creative Biolabs Original)

In Vivo Screening Platform

Creative Biolabs' in vivo phage display platform provides a powerful solution for identifying biologically active peptides that can navigate and function within complex living systems. Unlike in vitro models, our approach respects the full physiological landscape, accounting for vascular delivery, tissue penetration, immune clearance, and extracellular matrix interactions. This ensures that the ligands identified are not only selective but also functionally viable in vivo.

At the heart of the platform is a high-diversity phage display library with more than 109 unique clones, offering broad molecular diversity and increasing the chance of identifying peptides with high specificity and binding affinity. For muscle-targeting studies, this means the ability to uncover ligands that selectively bind to skeletal or cardiac muscle, distinguish between healthy and diseased tissues, or home to specific fiber types or metabolic states.

The platform is compatible with multiple screening goals—from targeting degenerative muscle conditions to enhancing drug delivery to muscular tissues—and is adaptable for a wide range of animal models, including mouse, rat, and custom species upon request. Researchers can use Creative Biolabs' well-characterized peptide and scFv libraries or integrate their custom libraries for a fully personalized campaign.

Should you want to learn more, please reach out.

Advantages

Working with Creative Biolabs means you benefit from:

Decades of combined phage display expertise

Customizable protocols for different muscle types and disease models

In vivo physiological relevance that surpasses traditional in vitro binding screens

Comprehensive data reporting, including next-gen sequencing analysis

Whether you're working on systemic peptide therapeutics, gene editing delivery tools, or biomarkers for muscle degeneration, we offer the scientific depth to bring your vision forward. For a deeper understanding, we encourage you to connect with us.

Deliverables

A detailed technical report documenting all methods, timelines, and observations
A list of enriched peptide or antibody sequences with associated read counts
Bioinformatics analysis, including motif identification and alignment to known proteins
Optional validation results (e.g., ELISA, immunostaining, in vivo imaging)
Consultation for next-step development strategies

If you're ready to advance your research with tissue-targeted ligands that work in vivo, partner with Creative Biolabs. Our team is here to help you navigate the complexity of muscle-targeting discovery with clarity, precision, and results that matter.

FAQ

Q: Can I use my own phage library in your screening service?
A: Yes, we accept client-supplied libraries pending QC review. We also offer in-house libraries for peptides and antibody fragments.
Q: What animal models do you support for muscle targeting?
A: We commonly use mice and rats for muscle targeting studies, including both healthy and disease-specific models. Other species can be discussed case-by-case.
Q: How long does the screening process take?
A: Typical turnaround time is 6–10 weeks, depending on the number of selection rounds and scope of validation.
Q: Can you differentiate between cardiac and skeletal muscle in selection?
A: Yes. By tailoring the tissue harvesting and circulation protocol, we can isolate tissue-specific binders for either or both muscle types.
Q: Will I retain IP rights to the peptides discovered?
A: Yes. Creative Biolabs operates under strict confidentiality, and all sequences and results identified during your project remain your intellectual property.